Inspection Record

Cascade Specialty Pharmacy LLC — FDA 483 Findings

US FDAInspected 2026-07-17Published 2026-07-31 4 findingsQuality unit oversightEquipment and facilityStability and storageLaboratory and QC controls

Inspectors Lillian S Wu · Youkeun KimThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not fully followed.

2Equipment and facility

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

3Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

4Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

About this record

Extracted automatically from the document US FDA published on 2026-07-31. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Cascade Specialty Pharmacy LLC company profile — full history US FDA documents, 2026 Go to Findings search